Bioventrix Attending ESC and TCT Congresses to Highlight Novel Transcatheter Approach for Heart Failure Treatment

SAN RAMON, Calif., August 27, 2014— BioVentrix, a pioneer of technologies and products for less invasive treatment of heart failure (HF), today announced its participation at the European Society of Cardiology (ESC) and Transcatheter Cardiovascular Therapeutics (TCT) congresses to showcase its next generation device. The Revivent-TC™ Ventricular Enhancement System reshapes the left ventricle (LV) by using a less invasive hybrid transcatheter approach to treat ischemic heart failure patients following a myocardial infarction. The Company will be exhibiting the devices at the ESC in Barcelona, August 30-September 2, with two stands: one on the main floor (Stand #M650) and one at the Emerging Technologies Showcase Area (Stand #N500).

The Company will also be participating in an interventional heart failure therapies scientific symposium at TCT in Washington, DC September 13-17. The focus of the session is left ventricular remodeling for treating the cause of Heart Failure progression. The Company will be presenting the Less Invasive Ventricular Enhancement (LIVE™) procedure, which will review the transcatheter approach to reshaping and restoring the LV.

Dr. Lon Annest, Chief Medical Officer for BioVentrix, will be on the distinguished panel and representing the Company at TCT for the scientific symposium (session III) entitled “Interventional Heart Failure Therapies, Part 1: Direct and Indirect Ventricular Remodeling” scheduled for 15 September 2014 from 3:42pm-6:01pm in Room 152 A/B. The presentation highlights are:

• Transcatheter Reshaping and Restoring the LV: Less Invasive Ventricular Enhancement Procedure scheduled from 5:22pm-5:34pm in Room 152A/B.

Dr. Annest will discuss the Company’s early clinical experience using the transcatheter hybrid procedure and will also reference the updated results from the Revivent™ Myocardial Anchoring System.

“I am particularly looking forward to our participation at this year’s ESC and TCT congresses, primarily because they coincide time-wise with the completion and submission of our European Pilot study which we now have preliminary follow up data from our hybrid transcatheter trial that can be compared to our surgical product results,” said Annest. "This gives the company an opportunity to disseminate more information to our colleagues on the Revivent device and the tremendous impact we have seen on a critically important patient cohort: those who suffer from post infarction ischemic cardiomyopathy and HF,” continued Annest. “Left ventricular volume reduction is proving to be an effective procedure that strongly impacts symptoms of HF when the heart is significantly enlarged and the patient has HF progressing on optimal medical therapy. By introducing a closed chest, hybrid transcatheter approach, the Revivent-TC system, we hope it can be offered to a much broader HF population those who are currently considered too frail or too elderly to consider an invasive procedure.

” To learn more about the LIVE™ therapy prior to the ESC and TCT congresses, please click here to view the Company’s sponsored symposium earlier this year at EuroPCR 2014 with the following faculty:

• Prof. Horst Sievert (Chair), CardioVascular Center (Frankfurt, Germany)
• Prof. Olaf Wendler, King’s College Hospital (London, UK): “The LIVE procedure: Technology and Techniques.”
• Prof. Helge Möllmann, Kerckhoff-Klinik (Bad Nauheim, Germany): “Revivent and Revivent-TC: Clinical results to date.”
• Prof. Petr Neuzil, Na Homolce Hospital (Prague, Czech Republic): “Clinical case reports and identifying the ideal patient candidate for the LIVE procedure.”

About the Revivent System and the LIVE Procedure
Placement of the Revivent System via the LIVE procedure obviates the need for more invasive surgery. Instead, small titanium anchors are placed along the outer surface of the heart and along one of the interior walls via a catheter-based approach. The anchors are then pulled toward one another, effectively excluding the scarred and non-functioning heart wall. The efficiency of the remaining heart muscle is immediately improved, by as much as 30-40 percent, according to data presented at the 2014 EuroPCR annual meeting.

Click here for procedural animation

NOTE: The Revivent Myocardial Anchoring System is approved for sale in Europe; it is not approved for sale in the United States. The Revivent-TC Ventricular Enhancement System is currently in clinical trial and is not yet commercially available.

# # #

Contact: David Schickling, VP of Sales and Marketing, +1-925-830-1000